LOXL2 and breast carcinoma: Preclinical evidence suggests that in vivo blocking LOXL2 both in vivo and in vitro is highly effective in preventing distant metastases in breast cancer through regulation of tissue inhibitor of metalloproteinase 1 (TIMP1), leading to increased TIMP1 and MMP 9 activity and facilitating ECM remodelling [82].